Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

National medicines policies - a review of the evolution and development processes.

Hoebert JM, van Dijk L, Mantel-Teeuwisse AK, Leufkens HG, Laing RO.

J Pharm Policy Pract. 2013 Jul 10;6:5. doi: 10.1186/2052-3211-6-5. Review.

2.

Future of the European Union regulatory network in the context of the uptake of new medicines.

Hoebert JM, Irs A, Mantel-Teeuwisse AK, Leufkens HG.

Br J Clin Pharmacol. 2013 Jul;76(1):1-6. doi: 10.1111/j.1365-2125.2012.04476.x. No abstract available.

3.

Reimbursement restriction and moderate decrease in benzodiazepine use in general practice.

Hoebert JM, Souverein PC, Mantel-Teeuwisse AK, Leufkens HG, van Dijk L.

Ann Fam Med. 2012 Jan-Feb;10(1):42-9. doi: 10.1370/afm.1319.

4.

Do rheumatoid arthritis patients have equal access to treatment with new medicines?: tumour necrosis factor-alpha inhibitors use in four European countries.

Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Bijlsma JW, Leufkens HG.

Health Policy. 2012 Jan;104(1):76-83. doi: 10.1016/j.healthpol.2011.10.011.

PMID:
22079753
5.

Quality and completeness of utilisation data on biological agents across European countries: tumour necrosis factor alpha inhibitors as a case study.

Hoebert JM, Mantel-Teeuwisse AK, van Dijk L, Laing RO, Leufkens HG.

Pharmacoepidemiol Drug Saf. 2011 Mar;20(3):265-71. doi: 10.1002/pds.2093.

PMID:
21351308

Supplemental Content

Loading ...
Support Center